KPRX

$1.73+6.13%

KIORA PHARMACEUTICALS INC

Market Cap

$8M

Live price × SEC shares (Aug 5, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

-0.12

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

0.5

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	0.00	0.00
Research & development	2,730	2,928	2,124	2,077	9,859
Total operating expenses	794	7,310	2,510	2,214	12,828
Operating income	(794)	(7,310)	(2,510)	(2,214)	(12,828)
Pretax income	(616)	(7,166)	(2,418)	(2,079)	(12,280)
Income tax	(643)	(650)	0	0	(1,293)
Net income	27	(6,517)	(2,418)	(2,079)	(10,987)
EPS (basic) ($)	0.01		(0.58)	(0.34)	(2.37)
EPS (diluted) ($)	0.01		(0.58)	(0.34)	(2.41)
Weighted avg. shares (basic)	4,290		4,175	6,178
Weighted avg. shares (diluted)	4,362		4,175	6,178

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 7, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 46 more quarters, back to Mar 2014, with Tormere Pro.

Corporate Events (8-K)

11 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 29, 2026 accepted 7:03 AM ET	1.01Material agreement7.01Reg FD disclosure	Document SEC ↗
Sep 8, 2026 accepted 7:05 AM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
Aug 19, 2026 accepted 7:01 AM ET	1.01Material agreement7.01Reg FD disclosure	Document SEC ↗
Aug 7, 2026 accepted 7:03 AM ET	2.02Earnings release	Document SEC ↗
Jun 18, 2026 accepted 7:02 AM ET	7.01Reg FD disclosure	Document SEC ↗
Jun 11, 2026 accepted 6:39 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
May 8, 2026 accepted 7:07 AM ET	2.02Earnings release	Document SEC ↗
Apr 7, 2026 accepted 7:01 AM ET	1.01Material agreement3.02Unregistered equity sale7.01Reg FD disclosure	Document SEC ↗
Apr 2, 2026 accepted 4:44 PM ET	5.02Officer / director change7.01Reg FD disclosure	Document SEC ↗
Mar 25, 2026 accepted 7:03 AM ET	2.02Earnings release	Document SEC ↗